Unfortunately, in other studies, Rituximab via the CHOP-mediated pathway did not provide beneficial outcomes for DLBCL patients with high Skp2 and low p27 expression (79). This evidence concerns the gene CDKN1B and diffuse large B-cell lymphoma.